Jung-Hyun Choi

Jung-Hyun Choi

Auto-generated profile, based on publicly available information

Jung-Hyun Choi

Department of Biochemistry, Chungbuk National University, Cheongju, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Molecular Cell
Verified
Journal Article
Closed access
XZXu Zhang
Xu Zhang
CCClément Chapat
Clément Chapat
PWPeng Wang
Peng Wang
JCJung-Hyun Choi
Jung-Hyun Choi
QLQian Li
Qian Li
NSNahum Sonenberg
Nahum Sonenberg

24 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NMNiaz Mahmood
Niaz Mahmood
JCJung-Hyun Choi
Jung-Hyun Choi
PWPei You Wu
Pei You Wu
SDSean W. Dooling
Sean W. Dooling
TWTrent A. Watkins
Trent A. Watkins
NSNahum Sonenberg
Nahum Sonenberg
The integrated stress response (ISR), a pivotal protein homeostasis network, plays a critical role in the formation of long-term memory (LTM). The precise mechanism by which the ISR controls LTM is not well understood. Here, we report insights into how the ISR modulates the mnemonic process by using targeted deletion of the activating transcription factor 4 (ATF4), a key downstream effector of the ISR, in various neuronal and non-neuronal cell types. We found that the removal of ATF4 from forebrain excitatory neurons (but not from inhibitory neurons, cholinergic neurons, or astrocytes) enhances LTM formation. Furthermore, the deletion of ATF4 in excitatory neurons lowers the threshold for the induction of long-term potentiation, a cellular model for LTM. Transcriptomic and proteomic analyses revealed that ATF4 deletion in excitatory neurons leads to upregulation of components of oxidative phosphorylation pathways, which are critical for ATP production. Thus, we conclude that ATF4 functions as a memory repressor selectively within excitatory neurons.

19 July 2024 in Science Advances
Verified
Journal Article
Open access
JCJung-Hyun Choi
Jung-Hyun Choi
JLJun Luo
Jun Luo
GHGeoffrey G. Hesketh
Geoffrey G. Hesketh
SGShuyue Guo
Shuyue Guo
APAngelos Pistofidis
Angelos Pistofidis
SJSeyed Mehdi Jafarnejad
Seyed Mehdi Jafarnejad
Viruses can selectively repress the translation of mRNAs involved in the antiviral response. RNA viruses exploit the Grb10-interacting GYF (glycine-tyrosine-phenylalanine) proteins 2 (GIGYF2) and eukaryotic translation initiation factor 4E (eIF4E) homologous protein 4EHP to selectively repress the translation of transcripts such as Ifnb1 , which encodes the antiviral cytokine interferon-β (IFN-β). Herein, we reveal that GIGYF1, a paralog of GIGYF2, robustly represses cellular mRNA translation through a distinct 4EHP-independent mechanism. Upon recruitment to a target mRNA, GIGYF1 binds to subunits of eukaryotic translation initiation factor 3 (eIF3) at the eIF3-eIF4G1 interaction interface. This interaction disrupts the eIF3 binding to eIF4G1, resulting in transcript-specific translational repression. Depletion of GIGYF1 induces a robust immune response by derepressing IFN-β production. Our study highlights a unique mechanism of translational regulation by GIGYF1 that involves sequestering eIF3 and abrogating its binding to eIF4G1. This mechanism has profound implications for the host response to viral infections.

23 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JCJung-Hyun Choi
Jung-Hyun Choi
Laura Marsal GarcíaLaura Marsal García
Laura Marsal García
EPEve Peraldi
Eve Peraldi
CWCaleb Walters
Caleb Walters
ZHZiying Huang
Ziying Huang
NSNahum Sonenberg
Nahum Sonenberg
Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder engendered by transcriptional silencing of the fragile X messenger ribonucleoprotein 1 ( FMR1 ) gene. Given the early onset of behavioral and molecular changes, it is imperative to know the optimal timing for therapeutic intervention. Case reports documented benefits of metformin treatment in FXS children between 2 and 14 y old. In this study, we administered metformin from birth to Fmr1 −/y mice which corrected up-regulated mitogen-2 activated protein kinase/extracellular signal-regulated kinase and mammalian/mechanistic target of rapamycin complex 1 signaling pathways and specific synaptic mRNA-binding targets of FMRP. Metformin rescued increased number of calls in ultrasonic vocalization and repetitive behavior in Fmr1 −/y mice. Our findings demonstrate that in mice, early-in-life metformin intervention is effective in treating FXS pathophysiology.

19 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RLReese Jalal Ladak
Reese Jalal Ladak
JCJung-Hyun Choi
Jung-Hyun Choi
JLJun Luo
Jun Luo
OCOwen J. Chen
Owen J. Chen
NMNiaz Mahmood
Niaz Mahmood
NSNahum Sonenberg
Nahum Sonenberg
A critical host response against viral infections entails the activation of innate immune signaling that culminates in the production of antiviral proteins. DNA viruses are sensed by the cytosolic pattern recognition receptor cyclic GMP–AMP synthase (cGAS), which initiates a signaling pathway that results in production of proinflammatory cytokines such as Interferon-β (IFN-β) and activation of the antiviral response. Precise regulation of the antiviral innate immune response is required to avoid deleterious effects of its overactivation. We previously reported that the 4EHP/GIGYF2 translational repressor complex reduces the translation of Ifnb1 mRNA, which encodes IFN-β, upon RNA viral infections. Here, we report a distinct regulatory mechanism by which 4EHP controls replication of DNA viruses by translational repression of the Cgas mRNA, which encodes the DNA viral sensor cGAS. We show that 4EHP is required for effective translational repression of Cgas mRNA triggered by miR-23a. Upon infection, 4EHP deficiency bolsters the elicited innate immune response against the diverse DNA viruses Herpes simplex virus 1 (HSV-1) and Vaccinia Virus (VacV) and concomitantly reduces their rate of replication in vitro and in vivo. This study elucidates an intrinsic regulatory mechanism of the host response to DNA viruses which may provide unique opportunities for countering viral infections.

7 September 2025 in bioRxiv
Verified
Preprint
Open access
KJKyeong Beom Jo
Kyeong Beom Jo
MAMohammed M. Alruwaili
Mohammed M. Alruwaili
DKDa-Eun Kim
Da-Eun Kim
YKYongjun Koh
Yongjun Koh
KYKwontae You
Kwontae You
DKDae-Kyum Kim
Dae-Kyum Kim
Background: Conventional chemotherapies remain the core therapeutic backbone of cancer treatment, yet the rapid emergence of chemoresistance often compromises their clinical efficacy. Although large-scale functional genomics has transformed precision oncology, existing reference maps rely predominantly on loss-of-function paradigms and lack systematic data on gain-of-function (GOF) events that commonly drive clinical resistance. Methods: To address this gap, we engineered a site-specific Bxb1 integrase landing-pad system in HeLa cells, enabling single-copy integration of a human proteome-wide library [18,388 open reading frames (ORFs)] at the AAVS1 locus under a uniform EF1α promoter. We systematically profiled cellular fitness across 16 chemotherapeutics. We integrated this GOF perturbation screen with bulk and single-cell RNA sequencing, FACS-based lysosomal functional screening, clinical cohort survival analyses, and preclinical xenograft modeling. Results: Stratified modeling of over 230,000 gene-drug interactions defined distinct functional categories that are strongly enriched for clinical cancer biomarkers and prognostic relevance. Global network analysis and organelle-specific lysosomal functional screening uncovered that chemotherapeutic agents, most prominently the nucleoside analog TAS-102 (Lonsurf), converge upon a shared survival hub centered on the BCL-2 family-associated autophagy-endolysosomal network. Mechanistically, TAS-102 triggered lysosomal activation as an adaptive survival response. Co-treatment with the BCL-2 family inhibitor ABT-263 (Navitoclax) attenuated this TAS-102-induced lysosomal response and synergistically reversed TAS-102 resistance across colorectal and pancreatic cancer models in vitro and in colorectal cell line- and patient-derived xenograft (CDX, PDX) models in vivo . Conclusions: Our study establishes an open-access, proteome-wide GOF reference atlas that systematically maps chemotherapeutic responses, recapitulates canonical resistance biology, and nominates rational drug combinations. This systems-genomics resource bridges massive-scale perturbation mapping with actionable target discovery, providing a translational framework to overcome therapeutic resistance and reprogram cancer drug responses.